Phase I clinical evaluation of @entity29601 in childhood XXXX .

@entity1 @entity295 @entity981 @entity424 @entity979 @entity5 @entity29601 @entity2800 @entity9638 @entity3052 @entity3638 @entity1778 @entity421 @entity6011 @entity2142 @entity236 @entity3043
@entity29601 ( @entity29601 ), a new lipid-soluble antitumor agent, was given by 15-30-minute infusion on a daily X 5 schedule to 47 @entity1 with refractory @entity5 and @entity1778 . The starting daily dose of 6 mg/m2 was escalated to 10 and 35 mg/m2 in @entity1 with @entity5 and @entity1778 , respectively. In @entity1 with @entity5 , myelosuppression was dose-limiting at a daily dose of 10 mg/m2. In @entity1 with @entity1778 , prolonged @entity3043 and @entity236 were observed at daily doses greater than or equal to 25 mg/m2. At these higher doses, significant @entity3638 associated with @entity295 was also seen. Corresponding increases of transaminases or alkaline phosphatase and significant @entity2142 were not noted. The maximum tolerated dose for this daily dose schedule was 9 mg/m2 in @entity1 with @entity5 and 25 mg/m2 in @entity1 with relapsed @entity1778 . Responses to @entity29601 included stabilization of disease in @entity421 , @entity6011 , @entity979 , and @entity424 . A @entity1 with juvenile chronic @entity2800 in @entity9638 converted back to the chronic phase. A @entity1 with @entity981 had a substantial decrease in cerebrospinal fluid blast count. @entity236 was achieved in @entity1 with @entity981 and @entity3052 ; however, remissions were not achieved. A phase II study of @entity29601 in @entity1 with @entity5 is now being performed by the Childrens Cancer Study Group.
